Autopsy report · NCT03520686

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

“There are no longer active subjects on QUILT-2.023. Data will be entered into clinicaltrials.gov within 1 year of the primary completion date.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 7 years 5 months before it stopped.
• 102 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

ImmunityBio, Inc.

Sponsor type

Industry

Conditions

Non Small Cell Lung Cancer

Interventions

NAI + Pembrolizumab; NAI + Nivolumab + Ipilimumab; NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel; Cisplatin/Carboplatin + Pemetrexed + Pembrolizumab + NAI; Cisplatin/Carboplatin + Pemetrexed + Atezolizumab + NAI; Carboplatin + Paclitaxel + Atezolizumab + Bevacizumab + NAI

Participants

102

Sites

31

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.